Clinical Trial Update: Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia [Phase 2]

View source ↗

Summary

Phase 2 trial update reports safety, tolerability, and efficacy data for PresbiDrops (CSF-1) in presbyopia. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• PresbiDrops (CSF-1) (CSF-1)

Snippet

Sponsor: Orasis Pharmaceuticals Ltd. | Conditions: Presbyopia | Phase 2 | Status: COMPLETED